Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc.
Neurocognitive functioning declines across central nervous system cancers, shaped by tumor type, location, and treatment. A ...
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES // VANCOUVER, BC, /PRNewswire/ -- ...
Researchers from the Alliance for Clinical Trials in Oncology have found that two targeted immunotherapy drugs lead to high ...
A new study led by UCLA investigators found that combining zanzalintinib, a targeted therapy drug, and atezolizumab, an ...
A review of recent literature shows bioengineering is reshaping oncology, from synthetic biology to nanomedicine, but what's ...